Daniel Grosz
Psychiatry · Encino, CANPI 1831200591
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement.
Across 4 payments — averaging $75.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$166
- Neuronetics, Inc.$137
Across 239 payments — averaging $13,717 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.7M
- AbbVie$474K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$411K
- Biohaven Pharmaceuticals, Inc.$221K
- Arbor Pharmaceuticals, Inc.$145K
- Sage Therapeutics, LLC$78K
- plus $288K from 9 others
What the payments were for
- Food & beverage$303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 2 | $166 |
| Neuronetics, Inc. | 2 | $137 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$132
How this compares
$303 in reported general payments places this provider in the 55th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $115,958 |
| ValiumDiazepam | 11 | $22,964 |
| Divalproex Sodium | 11 | $443 |
| Sertraline Hcl | 14 | $396 |
| Trazodone Hcl | 26 | $370 |
| Bupropion XlBupropion Hcl | 16 | $213 |
| Buspirone Hcl | 14 | $188 |
| Fluoxetine Hcl | 13 | $144 |
| Alprazolam | 28 | $126 |
| Lorazepam | 17 | $100 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $166 | $115,95812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Encino
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.